Kliničke studije za Rak krvi u državi Colorado
14 studija za Rak krvi traži sudionike na lokacijama u državi Colorado.
Gradovi u državi Colorado
Službeni tekst studije (engleski)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- University of Colorado Cancer Center ( Site 0021), Aurora
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- i još 15
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Colorado Blood Cancer Institute ( Site 2726), Denver
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT04728893Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Grand Valley Oncology, Grand Junction
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 17. ruj 2026. · NCT04242095Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT06001788A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. kol 2026. · NCT06823167A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Hospital Colorado, Aurora
- University of Colorado Hospital, Aurora
- Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 6. srp 2026. · NCT01351545Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Childrens Hospital of Colorado, Aurora
U tijeku regrutacijaOpažajna studija
Do 30 godina · Oba spola · Ažurirano 18. lip 2026. · NCT06579469A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- Children's Hospital Colorado, Aurora
U tijeku regrutacijaFaza 3
Od 2 do 18 godina · Oba spola · Ažurirano 5. svi 2026. · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT05735184Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Colorado, Denver
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. pro 2024. · NCT05476770Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.